Prostate Cancer Research - Symptoms, Genetics, Screening, Treatment, Information

Prostate Cancer Research Today is a free monthly online journal that collates and summarizes the latest research about Prostate Cancer, including details on symptoms, genetics, screening, treatment, information.


Prostate Cancer Research Today

Home

View Latest Issue

Information About Prostate Cancer

Books on Prostate Cancer

Advertising in Research Today

View Other Research Today Publications



Volume 2 (2005), Issue 7 (July)

  1. Treatment of androgen-independent, hormone-refractory prostate cancer with docetaxel in Japanese patients.
    Int J Clin Oncol, 10(3): 182-6. [Abstract] [Full-text]
  2. Out-of-field photon and neutron dose equivalents from step-and-shoot intensity-modulated radiation therapy.
    Int J Radiat Oncol Biol Phys, 62(4): 1204-16. [Abstract] [Full-text]
  3. Detailed urethral dosimetry in the evaluation of prostate brachytherapy-related urinary morbidity.
    Int J Radiat Oncol Biol Phys, 62(4): 981-7. [Abstract] [Full-text]
  4. Sequential evaluation of prostate edema after permanent seed prostate brachytherapy using CT-MRI fusion.
    Int J Radiat Oncol Biol Phys, 62(4): 974-80. [Abstract] [Full-text]
  5. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy.
    Int J Radiat Oncol Biol Phys, 62(4): 965-73. [Abstract] [Full-text]
  6. Health-related quality of life in men receiving prostate brachytherapy on RTOG 98-05.
    Int J Radiat Oncol Biol Phys, 62(4): 956-64. [Abstract] [Full-text]
  7. Assessment of residual error for online cone-beam CT-guided treatment of prostate cancer patients.
    Int J Radiat Oncol Biol Phys, 62(4): 1239-46. [Abstract] [Full-text]
  8. Comparative treatment planning on localized prostate carcinoma conformal photon- versus proton-based radiotherapy.
    Strahlenther Onkol, 181(7): 448-55. [Abstract] [Full-text]
  9. Results of three dimensional conformal radiotherapy and hormonal therapy for local recurrence after radical prostatectomy.
    Strahlenther Onkol, 181(7): 442-7. [Abstract] [Full-text]
  10. IMRT to escalate the dose to the prostate while treating the pelvic nodes.
    Strahlenther Onkol, 181(7): 431-41. [Abstract] [Full-text]
  11. Interobserver delineation variation using CT versus combined CT + MRI in intensity-modulated radiotherapy for prostate cancer.
    Strahlenther Onkol, 181(7): 424-30. [Abstract] [Full-text]
  12. Diverse biological effect and Smad signaling of bone morphogenetic protein 7 in prostate tumor cells.
    Cancer Res, 65(13): 5769-77. [Abstract] [Full-text]
  13. Targeted inhibition of the KLF6 splice variant, KLF6 SV1, suppresses prostate cancer cell growth and spread.
    Cancer Res, 65(13): 5761-8. [Abstract] [Full-text]
  14. Identification of leukocyte E-selectin ligands, P-selectin glycoprotein ligand-1 and E-selectin ligand-1, on human metastatic prostate tumor cells.
    Cancer Res, 65(13): 5750-60. [Abstract] [Full-text]
  15. Targeted biallelic inactivation of Pten in the mouse prostate leads to prostate cancer accompanied by increased epithelial cell proliferation but not by reduced apoptosis.
    Cancer Res, 65(13): 5730-9. [Abstract] [Full-text]
  16. Proteasome inhibitor MG132 induces death receptor 5 through CCAAT/enhancer-binding protein homologous protein.
    Cancer Res, 65(13): 5662-7. [Abstract] [Full-text]
  17. High activity of mitochondrial glycerophosphate dehydrogenase and glycerophosphate-dependent ROS production in prostate cancer cell lines.
    Biochem Biophys Res Commun, 333(4): 1139-45. [Abstract] [Full-text]
  18. Improved detection of prostate cancer using classification and regression tree analysis.
    J Clin Oncol, 23(19): 4322-9. [Abstract] [Full-text]
  19. Proliferative lesions of prostate: a multivariate approach to differential diagnosis.
    Pathol Oncol Res, 11(2): 103-7. [Abstract] [Full-text]
  20. A large cohort study of aspirin and other nonsteroidal anti-inflammatory drugs and prostate cancer incidence.
    J Natl Cancer Inst, 97(13): 975-80. [Abstract] [Full-text]
  21. Employment outcomes of men treated for prostate cancer.
    J Natl Cancer Inst, 97(13): 958-65. [Abstract] [Full-text]
  22. Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower.
    JAMA, 294(1): 66-70. [Abstract] [Full-text]
  23. New directions for critical internet health studies: representing cancer experience on the web.
    Sociol Health Illn, 27(4): 515-40. [Abstract] [Full-text]
  24. Does a delay in external beam radiation therapy after tissue diagnosis affect outcome for men with prostate carcinoma?
    Cancer, 104(2): 299-304. [Abstract] [Full-text]
  25. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy.
    Cancer, 104(2): 290-8. [Abstract] [Full-text]
  26. Radical prostatectomy: men's experiences and postoperative needs.
    J Clin Nurs, 14(7): 883-90. [Abstract] [Full-text]
  27. Finding more meaning: the antecedents of uncertainty revisited.
    J Clin Nurs, 14(7): 863-8. [Abstract] [Full-text]
  28. A combined genomewide linkage scan of 1,233 families for prostate cancer-susceptibility genes conducted by the international consortium for prostate cancer genetics.
    Am J Hum Genet, 77(2): 219-29. [Abstract] [Full-text]
  29. A germ line mutation that delays prostate cancer progression and prolongs survival in a murine prostate cancer model.
    Oncogene, 24(29): 4736-40. [Abstract] [Full-text]
  30. Differential effects of gonadotropin-releasing hormone (GnRH)-I and GnRH-II on prostate cancer cell signaling and death.
    J Clin Endocrinol Metab, 90(7): 4287-98. [Abstract] [Full-text]
  31. Protein C inhibitor (plasminogen activator inhibitor-3) expression in the CWR22 prostate cancer xenograft.
    Exp Mol Pathol, 79(1): 23-32. [Abstract] [Full-text]
  32. The validity of the family relationships index as a screening tool for psychological risk in families of cancer patients.
    Psychooncology, 14(7): 546-54. [Abstract] [Full-text]
  33. Inhibitors of tyrosine kinase inhibit the production of urokinase plasminogen activator in human prostatic cancer cells.
    APMIS, 113(5): 332-9. [Abstract] [Full-text]
  34. Androgen deprivation therapy for prostate cancer.
    JAMA, 294(2): 238-44. [Abstract] [Full-text]
  35. The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells.
    Proc Natl Acad Sci U S A, 102(28): 9890-5. [Abstract] [Full-text]
  36. Phosphorylation status of Fas-associated death domain-containing protein (FADD) is associated with prostate cancer progression.
    J Pathol, 206(4): 423-32. [Abstract] [Full-text]
  37. Incidentally detected prostate cancer in cystoprostatectomies: pathological and morphometric comparison with clinically detected cancer in totally embedded specimens.
    Hum Pathol, 36(6): 646-54. [Abstract] [Full-text]
  38. Local anesthesia in transrectal ultrasound-guided prostate biopsy: EMLA cream as a new alternative technique.
    Scand J Urol Nephrol, 39(2): 130-4. [Abstract] [Full-text]
  39. The National Prostate Cancer Register in Sweden 1998-2002: trends in incidence, treatment and survival.
    Scand J Urol Nephrol, 39(2): 117-23. [Abstract] [Full-text]
  40. Coagulopathy, following medical therapy, for carcinoma of the prostate.
    Hematology, 10(1): 65-8. [Abstract] [Full-text]
  41. Differences in glycosylation patterns of heat shock protein, gp96: implications for prostate cancer prevention.
    Cancer Res, 65(14): 6466-75. [Abstract] [Full-text]
  42. Human CTL epitopes prostatic acid phosphatase-3 and six-transmembrane epithelial antigen of prostate-3 as candidates for prostate cancer immunotherapy.
    Cancer Res, 65(14): 6435-42. [Abstract] [Full-text]
  43. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells.
    Cancer Res, 65(14): 6364-70. [Abstract] [Full-text]
  44. Activation of nuclear factor-kappaB contributes to induction of death receptors and apoptosis by the synthetic retinoid CD437 in DU145 human prostate cancer cells.
    Cancer Res, 65(14): 6354-63. [Abstract] [Full-text]
  45. A new three-dimensional ultrasound microimaging technology for preclinical studies using a transgenic prostate cancer mouse model.
    Cancer Res, 65(14): 6337-45. [Abstract] [Full-text]
  46. CaSm-mediated cellular transformation is associated with altered gene expression and messenger RNA stability.
    Cancer Res, 65(14): 6228-36. [Abstract] [Full-text]
  47. Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products.
    Cancer Res, 65(14): 6189-98. [Abstract] [Full-text]
  48. Quality assurance issues in radical prostatectomy.
    Eur J Surg Oncol, 31(6): 650-5. [Abstract] [Full-text]
  49. Oncolytic adenovirus CG7870 in combination with radiation demonstrates synergistic enhancements of antitumor efficacy without loss of specificity.
    Cancer Gene Ther, 12(8): 715-22. [Abstract] [Full-text]
  50. Dietary patterns and risk of prostate cancer in Ontario, Canada.
    Int J Cancer, 116(4): 592-8. [Abstract] [Full-text]
  51. Association of plasminogen with dipeptidyl peptidase IV and Na+/H+ exchanger isoform NHE3 regulates invasion of human 1-LN prostate tumor cells.
    J Biol Chem, 280(29): 27173-8. [Abstract] [Full-text]
  52. Absolute and relative dose-surface and dose-volume histograms of the bladder: which one is the most representative for the actual treatment?
    Phys Med Biol, 50(15): 3589-97. [Abstract] [Full-text]
  53. A particle swarm optimization algorithm for beam angle selection in intensity-modulated radiotherapy planning.
    Phys Med Biol, 50(15): 3491-514. [Abstract] [Full-text]
  54. Prostate cancer multi-feature analysis using trans-rectal ultrasound images.
    Phys Med Biol, 50(15): N175-85. [Abstract] [Full-text]
  55. Genetic variants of DNA repair genes and prostate cancer: a population-based study.
    Cancer Epidemiol Biomarkers Prev, 14(7): 1703-9. [Abstract] [Full-text]
  56. Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer.
    Cancer Epidemiol Biomarkers Prev, 14(7): 1697-702. [Abstract] [Full-text]
  57. Comparison of prostate-specific antigen and hormone levels among men in Singapore and the United States.
    Cancer Epidemiol Biomarkers Prev, 14(7): 1692-6. [Abstract] [Full-text]
  58. Initial experience with megavoltage (MV) CT guidance for daily prostate alignments.
    Int J Radiat Oncol Biol Phys, 62(5): 1517-24. [Abstract] [Full-text]
  59. Lack of benefit from a short course of androgen deprivation for unfavorable prostate cancer patients treated with an accelerated hypofractionated regime.
    Int J Radiat Oncol Biol Phys, 62(5): 1322-31. [Abstract] [Full-text]
  60. Comparing measures of acute bowel toxicity in patients with prostate cancer treated with external beam radiation therapy.
    Int J Radiat Oncol Biol Phys, 62(5): 1316-21. [Abstract] [Full-text]
  61. Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: the importance of PSA nadir before radiation.
    Int J Radiat Oncol Biol Phys, 62(5): 1309-15. [Abstract] [Full-text]
  62. Dose-volume analysis of predictors for chronic rectal toxicity after treatment of prostate cancer with adaptive image-guided radiotherapy.
    Int J Radiat Oncol Biol Phys, 62(5): 1297-308. [Abstract] [Full-text]
  63. Intraprostatic fiducials for localization of the prostate gland: monitoring intermarker distances during radiation therapy to test for marker stability.
    Int J Radiat Oncol Biol Phys, 62(5): 1291-6. [Abstract] [Full-text]
  64. Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
    Br J Cancer, 93(2): 173-7. [Abstract] [Full-text]
  65. Evaluation and management of prostate-specific antigen recurrence after radical prostatectomy for localized prostate cancer.
    Jpn J Clin Oncol, 35(7): 365-74. [Abstract] [Full-text]
  66. Anatomic distribution and pathologic characterization of small-volume prostate cancer (<0.5 ml) in whole-mount prostatectomy specimens.
    Mod Pathol, 18(8): 1022-6. [Abstract] [Full-text]
  67. Tectorigenin and other phytochemicals extracted from leopard lily Belamcanda chinensis affect new and established targets for therapies in prostate cancer.
    Carcinogenesis, 26(8): 1360-7. [Abstract] [Full-text]
  68. Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer.
    J Clin Oncol, 23(21): 4591-601. [Abstract] [Full-text]
  69. Malignant phyllodes tumor of the prostate.
    Arch Androl, 51(4): 295-8. [Abstract] [Full-text]
  70. Epigallocatechin gallate inhibits HIF-1alpha degradation in prostate cancer cells.
    Biochem Biophys Res Commun, 334(2): 543-8. [Abstract] [Full-text]
  71. Molecular cloning and characterization of STAMP2, an androgen-regulated six transmembrane protein that is overexpressed in prostate cancer.
    Oncogene, 24(31): 4934-45. [Abstract] [Full-text]
  72. Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience.
    Radiology, 236(2): 545-53. [Abstract] [Full-text]
  73. Biological variation of total prostate-specific antigen: a survey of published estimates and consequences for clinical practice.
    Clin Chem, 51(8): 1342-51. [Abstract] [Full-text]
  74. The role of anxiety in prostate carcinoma: a structured review of the literature.
    Cancer, 104(3): 467-78. [Abstract] [Full-text]
  75. Prostate cancer and the genomic revolution: Advances using microarray analyses.
    Mutat Res, 576(1): 66-79. [Abstract] [Full-text]
  76. The use of genetically engineered mouse models of prostate cancer for nutrition and cancer chemoprevention research.
    Mutat Res, 576(1): 111-9. [Abstract] [Full-text]
  77. Inguinal hernia repair with polypropylene mesh during radical retropubic prostatectomy: an easy and practical approach.
    BJU Int, 96(3): 330-3. [Abstract] [Full-text]
  78. Serum thyroid-stimulating hormone is elevated in men with Gleason 8 prostate cancer.
    BJU Int, 96(3): 328-9. [Abstract] [Full-text]
  79. Increasing the number of biopsy cores improves the concordance of biopsy Gleason score to prostatectomy Gleason score.
    BJU Int, 96(3): 324-7. [Abstract] [Full-text]
  80. Do all patients with high-grade prostatic intraepithelial neoplasia on initial prostatic biopsy eventually progress to clinical prostate cancer?
    BJU Int, 96(3): 320-3. [Abstract] [Full-text]
  81. New perioperative management reduces bleeding in radical retropubic prostatectomy.
    BJU Int, 96(3): 316-9. [Abstract] [Full-text]
  82. Analysis of peripheral blood for prostate cells after autologous transfusion given during radical prostatectomy.
    BJU Int, 96(3): 313-5. [Abstract] [Full-text]
  83. Age-specific reference levels of serum prostate-specific antigen and prostate volume in healthy Arab men.
    BJU Int, 96(3): 308-12. [Abstract] [Full-text]
  84. Tumour markers for managing men who present with metastatic prostate cancer and serum prostate-specific antigen levels of <10 ng/mL.
    BJU Int, 96(3): 303-7. [Abstract] [Full-text]
  85. Pretreatment PSA velocity and risk of death from prostate cancer following external beam radiation therapy.
    JAMA, 294(4): 440-7. [Abstract] [Full-text]
  86. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.
    JAMA, 294(4): 433-9. [Abstract] [Full-text]
  87. The influence of occupational exposure to pesticides, polycyclic aromatic hydrocarbons, diesel exhaust, metal dust, metal fumes, and mineral oil on prostate cancer: a prospective cohort study.
    Occup Environ Med, 62(8): 531-7. [Abstract] [Full-text]
  88. Usefulness of epithelial membrane antigen (EMA) to discriminate between perineural invasion and perineural indentation in prostatic carcinoma.
    Histopathology, 47(2): 159-65. [Abstract] [Full-text]
  89. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
    Cancer Chemother Pharmacol, 56(4): 415-20. [Abstract] [Full-text]
  90. Comparison of high-resolution echo-planar spectroscopic imaging with conventional MR imaging of prostate tumors in mice.
    NMR Biomed, 18(5): 285-92. [Abstract] [Full-text]
  91. Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure.
    J Clin Oncol, 23(22): 4975-9. [Abstract] [Full-text]
  92. Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer.
    Mitochondrion, 5(3): 143-53. [Abstract] [Full-text]
Place a permanent text-link or advertisement here.

© 2004-2013 Prostate Cancer Research Today. All Rights Reserved.



Prostate Cancer Research Today Archive:

Volume 1 (2004)
  Issue 1 (August)
  Issue 2 (September)
  Issue 3 (October)
  Issue 4 (November)
  Issue 5 (December)

Volume 2 (2005)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 3 (2006)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 4 (2007)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 5 (2008)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 6 (2009)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 7 (2010)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 8 (2011)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 9 (2012)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)
  Issue 8 (August)
  Issue 9 (September)
  Issue 10 (October)
  Issue 11 (November)
  Issue 12 (December)

Volume 10 (2013)
  Issue 1 (January)
  Issue 2 (February)
  Issue 3 (March)
  Issue 4 (April)
  Issue 5 (May)
  Issue 6 (June)
  Issue 7 (July)



Prostate Cancer Books

PROSTATE CANCER MEETS THE PROTON BEAM: A Patient's Experience

PROSTATE CANCER MEETS THE PROTON BEAM: A Patient's Experience